【摘要】 目的探讨地西他滨联合CAG预激方案(阿克拉霉素+阿糖胞苷+粒细胞集落刺激因子)治疗急性红白血病的临床效果。方法回顾性分析2007年1月至2013年9月苏州大学附属第一医院55例初治AEL患者,其中23例采用预激方案治疗,19例采用标准方案化疗,13例使用地西他滨联合CAG方案。结果使用地西他滨联合CAG方案的患者缓解率达到61.5%,总反应率(ORR)92.3%,缓解率及反应率优于传统方案组及预激方案组患者,但差异无统计学意义。结论地西他滨可能在急性红白血病的临床治疗中取得较好效果。更多还原

【Abstract】 Objective To discuss the clinical efficacy of the treatment with Decitabine and CAG priming induction regimen for acute erythroleukemia( AEL). Methods Fifty-five cases of newly diagnosed AEL patients were included in this study.Twenty-three patients were treated with priming induction regimen,19 patients were treated with classical routine chemotherapy,and the other 13 patients were treated with decitabine combined with CAG regimen. Results After chemotherapy with decitabine and CAG regimen,the complete remission rate was 61. 5% and the overall response rate 92. 3%,which were higher than those after the classical chemotherapy and priming induction regimen therapy,but the difference was not statistically significant. Conclusion Decitabine may have a better efficacy in clinical treatment of acute erythroleukemia.更多还原